Abcellera Biologics Inc (ABCL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 108,159 | 117,437 | 184,266 | 181,325 | 151,640 |
| Marketable Securities | 412,513 | 460,641 | 446,000 | 469,289 | 516,499 |
| Receivables | 41,456 | 47,310 | 40,005 | 33,616 | 31,373 |
| Other current assets | 133,012 | 116,757 | 94,707 | 67,140 | 43,371 |
| TOTAL | $695,140 | $742,145 | $764,978 | $751,370 | $742,883 |
| Non-Current Assets | |||||
| PPE Net | 427,358 | 424,020 | 347,102 | 340,429 | 331,263 |
| Investments And Advances | 93,301 | 90,374 | 81,567 | 82,297 | 84,084 |
| Intangibles | 87,127 | 88,068 | 88,998 | 89,919 | 100,383 |
| Other Non-Current Assets | 53,066 | 57,454 | 61,563 | 96,538 | 134,215 |
| TOTAL | $660,852 | $659,916 | $579,230 | $609,183 | $649,945 |
| Total Assets | $1,355,992 | $1,402,061 | $1,344,208 | $1,360,553 | $1,392,828 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 53,117 | 50,074 | 56,611 | 63,091 | 73,990 |
| TOTAL | $68,804 | $67,023 | $75,396 | $76,612 | $79,568 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 15,687 | 16,949 | 18,785 | 13,521 | 5,578 |
| Other Non-Current Liabilities | 138,438 | 138,744 | 64,834 | 62,212 | 72,239 |
| TOTAL | $323,150 | $327,962 | $245,830 | $227,857 | $235,166 |
| Total Liabilities | $391,954 | $394,985 | $321,226 | $304,469 | $314,734 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 299,335 | 298,833 | 298,485 | 297,988 | 295,366 |
| Common Shares | 794,469 | 791,668 | 790,068 | 777,171 | 772,832 |
| Retained earnings | -20,537 | 36,582 | 71,309 | 116,930 | 151,140 |
| Other shareholders' equity | -2,698 | -2,657 | -6,998 | -4,378 | -1,232 |
| TOTAL | $964,038 | $1,007,076 | $1,022,982 | $1,056,084 | $1,078,094 |
| Total Liabilities And Equity | $1,355,992 | $1,402,061 | $1,344,208 | $1,360,553 | $1,392,828 |